Experimental drug aims to tame overactive platelet production
NCT ID NCT06552429
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests two doses of peginterferon alfa-2b in 27 adults with essential thrombocythemia, a blood disorder causing too many platelets, who did not respond to or could not tolerate standard therapy. Participants receive weekly injections for up to 96 weeks. The study measures how the drug moves through the body, its safety, and whether it helps control platelet counts and reduce disease complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Peginterferon alfa-2b injection
What this could lead to
If successful, this could offer a new treatment option for people with essential thrombocythemia who cannot take or do not respond to standard therapy.
What could go wrong
This is a small early-phase trial with only 27 participants, so results may not apply broadly. The drug may cause side effects like flu-like symptoms or fatigue, and it is not yet proven to work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESSENTIAL THROMBOCYTHEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin First Hospital
RECRUITINGHarbin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Cancer Hospital
RECRUITINGHenan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nanfang Hospital, Southern Medical University
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking Union Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University People's Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGZhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Union Hospital affiliated to Fujian Medical University
RECRUITINGFujian, China
Contact Phone: •••-•••-•••• Email: •••••@•••••